首页> 美国卫生研究院文献>PLoS Neglected Tropical Diseases >Status of Onchocerciasis Transmission after More Than a Decade of Mass Drug Administration for Onchocerciasis and Lymphatic Filariasis Elimination in Central Nigeria: Challenges in Coordinating the Stop MDA Decision
【2h】

Status of Onchocerciasis Transmission after More Than a Decade of Mass Drug Administration for Onchocerciasis and Lymphatic Filariasis Elimination in Central Nigeria: Challenges in Coordinating the Stop MDA Decision

机译:在尼日利亚中部消除盘尾丝虫病和淋巴丝虫病超过十年的大规模药物管理之后盘尾丝虫病的传播状况:协调停止MDA决定的挑战

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThis study was undertaken in five onchocerciasis/lymphatic filariasis (LF) co-endemic local government areas (LGAs) in Plateau and Nasarawa, Nigeria. Annual MDA with ivermectin had been given for 17 years, 8 of which were in combination with albendazole. In 2008, assessments indicated that LF transmission was interrupted, but that the MDA had to continue due to the uncertain status of onchocerciasis transmission. Accordingly, assessments to determine if ivermectin MDA for onchocerciasis could be stopped were conducted in 2009.
机译:背景这项研究是在尼日利亚高原和纳萨拉瓦的五个盘尾丝虫病/淋巴丝虫病(LF)地方病地方政府地区(LGA)进行的。给予伊维菌素的年度MDA达17年,其中有8种与阿苯达唑合用。 2008年的评估表明,LF传播被中断,但是由于盘尾丝虫病传播的不确定状态,MDA必须继续进行。因此,2009年进行了评估,以确定是否可以停止伊维菌素MDA用于盘尾丝虫病的治疗。

著录项

相似文献

  • 外文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号